Pharmacokinetic-Pharmacodynamic modelling of intracellular Mycobacterium tuberculosis growth and kill rates is predictive of clinical treatment duration

Aljayyoussi, Ghaith, Jenkins, Victoria, Sharma, Raman, Donnellan, Samantha, Ward, Steve ORCID: https://orcid.org/0000-0003-2331-3192 and Biagini, Giancarlo ORCID: https://orcid.org/0000-0001-6356-6595 (2017) 'Pharmacokinetic-Pharmacodynamic modelling of intracellular Mycobacterium tuberculosis growth and kill rates is predictive of clinical treatment duration'. Scientific Reports, Vol 7, Issue 502.

Preview	Text Scientific_Reports_SREP-16-34010B.pdf - Accepted Version Available under License Creative Commons Attribution. Download (2MB) | Preview
Preview	Image (supplimentary material) Scientific_Reports_SREP-16-34010B suppliments.pdf - Accepted Version Available under License Creative Commons Attribution. Download (2MB) | Preview
Preview	Text Scientific_Reports_Pharmacokinetic_7_502_29th_March.pdf - Published Version Available under License Creative Commons Attribution. Download (2MB) | Preview

Abstract

Tuberculosis (TB) treatment is long and complex, typically involving a combination of drugs taken for 6 months. Improved drug regimens to shorten and simplify treatment are urgently required, however a major challenge to TB drug development is the lack of predictive pre-clinical tools. To address this deficiency, we have adopted a new high-content imaging-based approach capable of defining the killing kinetics of first line anti-TB drugs against intracellular Mycobacterium tuberculosis (Mtb) residing inside macrophages. Through use of this pharmacokinetic-pharmacodynamic (PK-PD) approach we demonstrate that the killing dynamics of the intracellular Mtb sub-population is critical to predicting clinical TB treatment duration. Integrated modelling of intracellular Mtb killing alongside conventional extracellular Mtb killing data, generates the biphasic responses typical of those described clinically. Our model supports the hypothesis that the use of higher doses of rifampicin (35 mg/kg) will significantly reduce treatment duration. Our described PK-PD approach offers a much needed decision making tool for the identification and prioritisation of new therapies which have the potential to reduce TB treatment duration.

Item Type:	Article
Subjects:	QV Pharmacology > QV 4 General works W General Medicine. Health Professions > W 20.5 Biomedical research WA Public Health > Preventive Medicine > WA 110 Prevention and control of communicable diseases. Transmission of infectious diseases WF Respiratory System > Tuberculosis > WF 200 Tuberculosis (General) WH Hemic and Lymphatic Systems > Lymphatic System > WH 650 Reticuloendothelial system
Faculty: Department:	Biological Sciences > Department of Tropical Disease Biology
Digital Object Identifer (DOI):	https://doi.org/10.1038/s41598-017-00529-6
Depositing User:	Stacy Murtagh
Date Deposited:	05 Apr 2017 10:05
Last Modified:	03 Aug 2021 13:55
URI:	https://archive.lstmed.ac.uk/id/eprint/6915

Statistics

View details

Actions (login required)

Edit Item